DRIO

DarioHealth NASDAQ: DRIO reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the first quarter and $5.4 million a year earlier, as the company continued to shift away from pharmaceutical services revenue toward recurring B2B2C business.

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $2.4 per share a year ago.

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition Commercial momentum with three significant wins in recent weeks, led by a top-5 national health plan expansion with the potential to approximately triple Dario's potential revenue opportunity — its third such expansion — plus a 5th Fortune 50 client and a new health insurer via the Amwell channel Expanded into provider-backed clinical care delivery, accessing a larger portion of the healthcare value chain and increasing the potential revenue opportunity per client Pro forma cash of $36.8 million following $22.8 million net proceeds from at-the-market registered direct financing with participation from existing long-term shareholders and new fundamental institutional investors completed in July 2026 Conference call today, August 11, 2026 at 8:30 am ET NEW YORK, Aug. 11, 2026 /PRNewswire/ -- DarioHealth  Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the second quarter ended June 30, 2026. "We believe that Dario has reached an important stage where the investments made in our technology, product, and distribution infrastructure are compounding positive momentum," said Erez Raphael, Chief Executive Officer of Dario.

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services NEW YORK, Aug. 4, 2026 /PRNewswire/ --  DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometabolic platform with the launch of Dario Women™ and Dario Sleep™. The two new programs address important drivers of cardiometabolic health through an integrated care experience combining AI-powered engagement, behavioral support and access to licensed healthcare providers.

Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2026 and will host a conference call and webcast at 8:30 a.m.

First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platform Commercial availability expected Fall 2026, with revenue contribution anticipated late 2026 and ramping through 2027 Launch addresses a market in which employers and health plans are reducing GLP-1 coverage and members are increasingly accessing care through consumer channels Available through three channels: Dario's direct-to-consumer shop, health plan marketplaces and employer B2B2C programs NEW YORK, July 30, 2026 /PRNewswire/ --  DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the launch of Dario's Integrated GLP-1 Program, the first commercial offering built on the Company's recently announced collaboration with Beluga Health ("Beluga"). Dario has supported members on GLP-1 therapy for years through AI-powered engagement, connected monitoring, nutrition and behavioral coaching.

DarioHealth (DRIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investor NEW YORK, July 22, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that it has entered into securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock (or common stock equivalents in lieu thereof), at a price of $6.80 per share, in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering"). A member of the Company's Board of Directors participated in the Offering by purchasing 14,430 shares of the Company's common stock at a purchase price of $6.93 per share.

Contract award for over 100,000 eligible employees marks Dario's fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition management Program expected to launch Fall 2026, with revenue contribution beginning by year-end and ramping through 2027 NEW YORK, July 16, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/or hypertension. The program will be available to more than 100,000 eligible employees and is expected to launch in Fall 2026.

DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for Dario Dario IQ's AI-driven personalization increases member engagement by 40% and improves member retention by 20% by leveraging 13+ billion proprietary real-world healthcare data points NEW YORK, July 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the Company expects broader deployment of DarioIQ™, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-to-Consumer ("B2B2C") recurring revenue by approximately 10% to 15% from existing customers, before the impact of future customer wins or additional condition expansions.     While Dario continues to demonstrate success with its land-and-expand strategy with existing enterprise customers through its multi-condition platform, DarioIQ creates an additional opportunity to lift B2B2C annual recurring revenues from current clients.